Adding lapatinib to a chemotherapy regimen has proven to increase its anti-tumor activity, as evidenced by the FDA and EMA approval of lapatinib in combination with capecitabine for previously treated, metastatic, HER2-overexpressing breast cancer [14, 15]. This evidence concerns the gene ERBB2 and breast carcinoma.